REG - Diaceutics PLC - Conversion of Convertible Loan Notes & TVR

DiaceuticsAnnouncement

05/04/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE3696Ha&default-theme=true

RNS Number : 3696H  Diaceutics PLC  05 April 2022

 

5 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

 

 
Conversion of Convertible Loan Notes & Total Voting Rights

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), the diagnostic
commercialisation company, announces that a holder ("Noteholder") of £100,000
of convertible loan notes issued by Diaceutics on 15 October 2018 ("CLN's"),
has elected to convert the loan note principal plus interest accrued over the
period into 233,508 ordinary shares of £0.002 each ("Ordinary Shares"), at a
25% discount to the Company's IPO price in accordance with the instrument's
terms, being a price of £0.57 per Ordinary Share.

 

In accordance with the authority granted to the Directors at the Annual
General Meeting of shareholders on 19 May 2021, 233,508 new Ordinary Shares
(the "Conversion Shares") will be issued to the Noteholder. Application has
been made for the admission of the Conversion Shares to trading on AIM, with
such admission expected to become effective on 8 April 2022 ("Admission").

The Company will have no outstanding convertible loan notes on the allotment
of the above Conversion Shares.

 

Following Admission, the total issued share capital of the Company will
consist of 84,302,431 Ordinary Shares of £0.002 each. This number may be used
by shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Enquiries:

 Diaceutics PLC
 Nick Roberts, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBSGDSSSGDGDU